Wet Age-Related Macular Degeneration (Wet AMD) market is expected to reach USD 18 billion by 2034

Wet age-related macular degeneration (Wet AMD) is a chronic, progressive eye disorder and one of the leading causes of severe vision loss in people over 60. Unlike the dry form of AMD, Wet AMD is characterized by the growth of abnormal blood vessels under the retina that leak fluid or blood, leading to rapid central vision loss. While Wet AMD accounts for only about 10-15% of all AMD cases, it causes the majority of severe vision impairment associated with the disease.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72241

Over the past two decades, the introduction of anti-VEGF (vascular endothelial growth factor) therapies has revolutionized Wet AMD treatment, significantly improving visual outcomes and reducing the risk of blindness. With rising global aging populations, increased awareness, and continuous advancements in ophthalmology, the Wet AMD market is set for steady expansion. Emerging therapeutic modalities, extended dosing regimens, and digital health integration are further reshaping the outlook for patients and providers.

Market Overview
According to Exactitude Consultancy, the global Wet Age-Related Macular Degeneration Market was valued at USD 10 billion in 2024 and is projected to reach USD 18 billion by 2034, growing at a CAGR of 6.2% between 2025 and 2034.

Key Highlights
• Revolution in care: Anti-VEGF therapies remain the cornerstone of treatment, with continuous improvements in efficacy and convenience.
• Drivers: Growing elderly population, advancements in biologics and sustained-delivery therapies, and rising screening initiatives.
• Challenges: High treatment costs, need for repeated injections, and limited adoption in low-income regions.
• Leading players: Regeneron, Roche/Genentech, Novartis, and Bayer dominate the market with established and emerging anti-VEGF therapies.

Segmentation Analysis
The Wet AMD market can be segmented by therapy type, end use, and region.

By Therapy Type
• Anti-VEGF therapies (ranibizumab, aflibercept, brolucizumab, bevacizumab)
• Combination therapies (anti-VEGF + angiopoietin inhibitors)
• Gene therapies and regenerative medicine
• Supportive care (laser photocoagulation, photodynamic therapy)

By End Use
• Hospitals
• Specialty eye clinics
• Ambulatory surgical centers
• Homecare monitoring systems

Segmentation Summary
Anti-VEGF therapies account for the majority of market revenue, with aflibercept and ranibizumab widely used across regions. Newer agents like brolucizumab and faricimab offer extended dosing intervals, reducing patient burden. Gene therapies and regenerative approaches represent emerging frontiers, with strong growth potential in the next decade.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72241/wet-age-related-macular-degeneration-wet-amd-market

Regional Analysis
North America
• Largest market, driven by advanced healthcare systems, high prevalence of AMD, and strong adoption of biologics.
• The U.S. leads with FDA-approved therapies and robust clinical trial pipelines.
Europe
• Strong adoption in Germany, the U.K., and France, supported by public healthcare coverage and rising elderly populations.
• EMA approvals for innovative biologics are accelerating market growth.
Asia-Pacific
• Expected to record the fastest CAGR during 2025-2034.
• Rising prevalence of AMD in China and Japan, coupled with healthcare modernization in India, is fueling growth.
• Japan and South Korea are early adopters of extended-dosing biologics and advanced imaging technologies.
Middle East & Africa
• Moderate growth, with GCC countries leading adoption through advanced ophthalmology centers.
• Limited access to biologics remains a challenge in many African regions.
Latin America
• Brazil and Mexico dominate, supported by growing healthcare investments and ophthalmology programs.
Regional Summary
While North America dominates today, Asia-Pacific is projected to grow the fastest, driven by demographic shifts, healthcare improvements, and increasing adoption of biologics.

Market Dynamics
Key Growth Drivers
1. Aging populations - Rapid global demographic shifts are increasing the prevalence of AMD.
2. Advances in biologics - Extended-dosing anti-VEGF therapies and dual-action biologics improve patient compliance.
3. Innovations in diagnostics - OCT and AI-based retinal imaging are enabling earlier detection and treatment initiation.
4. Rising public health initiatives - Awareness campaigns and screening programs are expanding diagnosis rates.

Key Challenges
1. High treatment costs - Anti-VEGF injections and long-term management remain expensive.
2. Treatment burden - Frequent intravitreal injections create compliance issues for patients.
3. Access disparities - Emerging markets face limited availability of advanced biologics and diagnostic tools.

Latest Trends
• Extended dosing intervals: Faricimab and other new biologics reduce injection frequency.
• Combination therapies: Targeting VEGF and Ang-2 pathways for enhanced efficacy.
• Gene therapies: Trials are underway for one-time or long-lasting Wet AMD treatments.
• Digital ophthalmology: Remote monitoring and AI-driven diagnostic platforms are expanding patient access.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72241

Competitor Analysis
Major Players in the Wet AMD Market
• Regeneron Pharmaceuticals, Inc. (Eylea/aflibercept)
• Roche/Genentech (Lucentis/ranibizumab, Vabysmo/faricimab)
• Novartis AG (Beovu/brolucizumab)
• Bayer AG (co-commercialization of aflibercept)
• Allergan (AbbVie Inc.)
• Kodiak Sciences Inc.
• Adverum Biotechnologies, Inc.
• Lineage Cell Therapeutics Inc.
• Pfizer Inc.
• Santen Pharmaceutical Co., Ltd.

Competitive Dynamics
Regeneron and Bayer dominate with aflibercept (Eylea), while Roche/Genentech lead with ranibizumab and faricimab, a dual inhibitor offering extended dosing. Novartis competes with brolucizumab, though safety concerns have tempered uptake. Emerging biotech firms like Kodiak Sciences and Adverum are advancing gene therapy pipelines. Partnerships, licensing deals, and clinical trial expansions remain central to competitive strategies.

Conclusion
The Wet Age-Related Macular Degeneration Market is projected to grow from USD 10 billion in 2024 to USD 18 billion by 2034, at a CAGR of 6.2%.

Key opportunities include:
• Expanding adoption of extended-dosing biologics and dual-action therapies.
• Scaling gene therapy and regenerative approaches to reduce treatment burden.
• Leveraging AI and digital imaging tools for early diagnosis and patient monitoring.
• Strengthening access in emerging markets through healthcare modernization and cost-effective solutions.

While challenges such as high treatment costs and compliance issues persist, continuous innovation in biologics and diagnostics ensures a strong growth outlook.

In conclusion, the Wet AMD Market is on a transformative path, where advanced therapies, digital tools, and global awareness will reduce blindness risks and improve outcomes for millions of patients worldwide.

This report is also available in the following languages : Japanese (滲出型加齢黄斑変性(ウェットAMD)市場), Korean (습성 연령관련 황반변성(습성 AMD) 시장), Chinese (湿性年龄相关性黄斑变性(湿性AMD)市场), French (Marché de la dégénérescence maculaire liée à l'âge (DMLA) humide), German (Markt für feuchte altersbedingte Makuladegeneration (feuchte AMD)), and Italian (Mercato della degenerazione maculare senile umida (AMD)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/reports/72241/wet-age-related-macular-degeneration-wet-amd-market#request-a-sample

Our More Reports:

Plaque Psoriasis in 68 Market
https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market

Pharmaceutical Drugs Market
https://exactitudeconsultancy.com/reports/73644/pharmaceutical-drugs-market

Parkinson's Disease Market
https://exactitudeconsultancy.com/reports/73645/parkinson-s-disease-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.